Feminist working on access to treatment issues. Follow issues related to generic production and patents closely. Views are my own.
Joined January 2013
- Tweets1.7K
- Following596
- Followers1.5K
- Likes572
Pinned Tweet
In area of IP, PublicHealth & access to medicines, Modi govt sh consider its independence 2 be of utmost importance tinyurl.com/hwsdrdr
To reporters who ask: US President’s tweet on 100% import tariffs on pharma products targets branded drugs, leaving affordable generics out. An unbranded generic? A Phoenix—unseen in health systems.
1
138
The tweet nitter.gq/WhiteHouse/status/1971… appears to cover both patented and generic medicines from any country. Best to wait for the full text on October 1.
“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America...” - President Donald J. Trump
1
63
The US imposes 100% tariffs on generic medicines from India. Result? Millions of US patients face skyrocketing costs 💊💉Share prices may bounce back, but patients bear the real cost of treatment interruptions. #AccessToMedicines
3
69
LMenghaney retweeted
"Imagine a new HIV prevention tool existed that could – if it reached the right people – flick the switch to prevent almost all new HIV cases across the world...
@_HassanF , Leena Menghaney, and Bellinda Nkoana brilliant piece @HealthJusticeIn
spotlightnsp.co.za/2025/09/0…
100+ Doctors Who Worked in Gaza Demand Global Action as 'Colleagues Are Starved and Shot by Israel' open.substack.com/pub/zeteo/…
1
57
LMenghaney retweeted
Patients with Spinal Muscular Atrophy are hopeful of getting access to generic versions of Roche’s patented drug Risdiplam, following Delhi High Court’s denial of an interim injunction request from the Swiss drugmaker. Click here to read more: @jo_da123
trib.al/zBEx2ks
LMenghaney retweeted
In the noise over tariffs, intellectual property (IP) has not yet been stated out loud as a negotiating tool, but it waits in the wings, say economists. This, even as the clock ticks on the USTR's Special 301 report.#pharma
IP in the time of tariff wars thehindubusinessline.com/spe…
Cystic Fibrosis Patients and Families Urge Court to Ensure Access to Life-Saving Drug accesstomedicinesindia.wordp…
35
Supreme Court Order Risks Interrupting Treatment for Young Woman with Spinal Muscular Atrophy accesstomedicinesindia.wordp…
1
41
LMenghaney retweeted
Today on #WorldDiabetesDay, we’re at @NovoNordisk offices in Johannesburg w/ a message:
📢Resume the supply of insulin pens in South Africa
AND
📢DROP THE PRICE to $1/pen so ALL people living w/ #diabetes can manage their treatment.
Insulin pens shouldn’t be a luxury!
On our way to the @novonordisk office in Joburg to demand that they stop the #DoubleStandard in Diabetes Tx. Our demand stop the profiterring and supply the insulin pen @$1 to South Africa! – at Johannesburg, South Africa
76
LMenghaney retweeted
NEW: One miracle drug could create a fiscal crisis in America.
Ozempic could end obesity...bankrupt Medicare, blow up state budgets and increase premiums for everyone.
It’s because Big Pharma is ripping us off. The drug costs $936 in the US—but nearly 10x less everywhere else.
South Africa's Competition Commission continues to deliver access by investigating anti-competitive "evergreening" practices in the patent system, but we need patent laws & patent examiners to prevent ever-greening wh extend monopolies on known meds! @MSF_access @HealthJusticeIn
We scored a big win when J&J dropped their patent on #TB medicine after the @CompComSA initiated a probe. 20 years ago, a similar case helped drive down #antiretroviral prices, write @_HassanF and Leena Menghaney. @HealthJusticeIn @MSF @HealthJusticeIn
spotlightnsp.co.za/2024/08/3…
Colombia’s president signs law to strengthen pharmaceutical sector finance.yahoo.com/news/colom… via @YahooFinance
2
85
This is a momentous day for people with DR-TB. India will finally replace many of the longer, less-effective tx by offering safer and shorter BPaLM regimen that is more effective in curing this deadly disease.
MSF welcomes NTEP's step to introduce BPaL & BPaL/M - a significant breakthrough in the battle against MDR in India. The next step is to also introduce delamanid based short oral regimens for children and as an alternative for people who cannot tolerate bedaquiline or linezolid.
India is getting ready to roll out BPaL regimen for all M/XDRTB patients - training to begin this month. This should improve treatment outcomes & help thousands of patients. Scaling up NAAT coverage will be an essential element of the strategy @WHO @StopTB @TBHDJ @MoHFW_INDIA
LMenghaney retweeted
ViiV-GSK attack the COMPULSORY LICENSE of dolutegravir - to treat HIV - in Colombia, seeking its judicial annulment. We call to action to defend the license.
sign here:
👉 goo.su/8G2VQ
#GlaxoViiVDropTheCase
#DTGinColombiaNow
#aids2024
LMenghaney retweeted
Happening now at #AIDS2024!
We’re asking @GileadSciences to immediately license groundbreaking #HIV prevention drug, #lenacapavir, to make it affordable for all! #PeopleOverProfits
LMenghaney retweeted
Hooray! The Indian Patent Office just rejected @JNJNews's attempt to extend its monopoly on the paediatric version of #tuberculosis drug #bedaquiline, thanks to a patent challenge by @dnpplus & #TB survivor & activist Ganesh Acharya 👏
msfaccess.org/msf-welcomes-i…